Page 41 - Making Progress News Today

Feb 18, 2021 8:36am Cognates buyout-to-be comes shortly after the company plotted cell and gene therapy manufacturing expansions in Europe and the U.S. (Cognate BioServices) Just a few weeks after Cognate BioServices moved to beef up its cell and gene therapy manufacturing, the company has attracted a buyer eager to tap that expertise. Charles River Laboratories agreed to throw down $875 million cash for Cognate in a deal designed to create a one-stop-shop in cell and gene therapies. Cognates ...

In letters published in The New England Journal of Medicine, Pfizer and Moderna acknowledged that laboratory experiments showed their mRNA vaccines aren't as potent against the aggressive new COVID-19 variant identified in South Africa. Wall Street analysts are worried.

While Mexico is receiving small shipments of AstraZeneca's COVID-19 vaccines from overseas, two large shipments of the active ingredient used to make it remain unused. The holdup? Problems at a domestic factory tasked with finishing the shots, according to Mexico’s foreign minister Marcelo Ebrard.

After a coronavirus vaccine supply feud between top officials in Europe and COVID-19 vaccine player AstraZeneca, officials there are doubling down on their purchase of an alternative technology. This week, the bloc finalized the purchase of 350 million additional mRNA vaccine doses.

It's not just the worrisome data showing AstraZeneca’s COVID-19 vaccine was largely ineffective against the aggressive South African variant that worries some analysts. Inconsistent manufacturing could complicate the company's bid to win over the FDA for a U.S. launch.

Feb 16, 2021 8:19am A British audit of Serum Institute of Indias manufacturing processes could tee up exports of Indian-made COVID-19 shots to the U.K. and Europe. (nevodka/iStock/Getty Images Plus/Getty Images) AstraZeneca set up a globetrotting supply network for its COVID-19 vaccine to deliver doses around the world, but it hasnt tapped regional producers to ease delivery shortfalls elsewhere. But that could change—and soon. British regulators are inspecting one of the drugmakers biggest ...

Sanofi Ventures led a $4 million seed financing in i20 last year. (Sanofi) Sanofi has teamed up with i2O Therapeutics to create oral nanobody-based medicines. The partners will use i2O’s platform for protecting peptides and proteins to end the need for nanobodies to be given via intravenous or subcutaneous injections. Nanobodies are therapeutic proteins based on single-domain antibody fragments. Like antibodies, the molecules are typically administered via injections, but advocates of the mod...

The FDA approved G1s Cosela on Friday. (FDA) Despite the ever-growing use of targeted oncology drugs, chemotherapy is still widely used in lung cancer—and it still comes with potentially severe side effects. G1 Therapeutics just won FDA approval for a therapy that can help combat one of the most serious. G1s Cosela scored a green light to reduce the bone marrow damage that can come along with chemo. Given ahead of certain chemotherapy regimens to patients with extensive-stage small-cell ...

General Electric Company (NYSE: GE) is having a rare green day Tuesday, gaining more than 12 percent after the company announced a new strategic plan for its stake in Baker Hughes a GE Co (NYSE: BHGE). Unfortunately for GE investors, experts are saying GE’s situation may be worse than... Read More... Dont Miss Any Updates! News Directly in Your Inbox Subscribe to:

Why ‘Intentions’ Might Be Better for Your Mental Health Than New Year’s Resolutions Betsey OBrien © The Mighty photo of woman on shoreline looking out to sea at sunrise January is the time we encourage ourselves to set goals for the year ahead. Usually, that’s a very positive activity that gives us a chance to look forward with hope and savor the possibilities that lie ahead. But what seems like a natural exercise for many people might feel quite different for someone...